Lucia Zamorano, MD, PLC

Brain & Spine Surgery

MICHIGAN BRAIN & SPINE

SURGERY CENTER

  • Phone: (248) 723-2477 | Fax: (248) 681-3209
  •   New Patient Forms »  
  •   Leave Feedback »     Review Us »  
Menu
  • Home
  • About
    • About Dr. Zamorano
    • Testimonials
    • Practice Members
    • Published Articles
    • Community Events
    • Press
    • Close
  • Specialties
    • Auto & Workman’s Compensation
    • Brain & Spine Tumors
    • Cervical Spine Surgery
    • Computer Assisted Surgery
    • Endoscopic Spine Surgery
    • Endoscopy Brain
    • Endoscopic Lumbar Fusion
    • Endoscopy Spine
    • Epilepsy Surgery
    • Gamma Knife
    • Intra-Operative MRI
    • Kyphoplasty
    • Laser Surgery
    • Low Grade Gliomas
    • Lumbar Spine Surgery
    • Minimally Invasive Surgery
    • Movement Disorders
    • Neurosurgical Oncology
    • Pain Management
    • Pituitary Tumors
    • Radio Surgery
    • Robotic Surgery
    • Robotics Endoscopic Spine Surgery
    • Skull Base Surgery
    • Spinal Cord Injury
    • Spine Surgery
    • StemWave Therapy
    • Stereotactic Surgery
    • Traumatic Brain Injury
    • Trigeminal Neuralgia
    • Close
  • Forms
    • New Patient Information
    • Medication Protocol
    • Close
  • Patient Education
    • Category Index
    • Educational Articles
    • Hospital Links
    • Health Library
    • Innovative Technologies
    • Close
  • Blog
  • Locations
  • Careers
  • Contact Us
    • VIP Concierge Program
    • Close
    • Close
You are here: Home / Archives for Alzheimer Disease

Link Between Concussions and Alzheimer’s Disease

Researchers find link between concussions and Alzheimer’s disease

Boston University School of Medicine

New research has found concussions accelerate Alzheimer’s disease–related brain atrophy and cognitive decline in people who are at genetic risk for the condition. The findings, which appeared in the journal Brain, show promise for detecting the influence of concussion on neurodegeneration.

Moderate–to–severe traumatic brain injury is one of the strongest environmental risk factors for developing neurodegenerative diseases such as late–onset Alzheimer’s disease, although it is unclear whether mild traumatic brain injury or concussion also increases this risk.… [Continue Reading]

Filed Under: Alzheimer Disease Tagged With: Alzheimer, Alzheimer's Disease

Could you prevent cognitive decline by preventing gum disease?

dementiaTakeaway

  • Cognitive decline in early Alzheimer’s disease (AD) is linked to periodontitis, independent of baseline cognition.

Study design

  • 60 community residents (mean 77.7±8.6 years; 51% men) with mild/moderate AD underwent cognitive, dental, and blood testing at baseline and at 6 months (n=52).

Key results

  • Baseline periodontitis (in 37.3%), diagnosed by a dental hygienist blinded to cognitive outcomes, was associated with a sixfold increase in rate of cognitive decline on the ADAS-cog and with increase in blood pro-inflammatory markers over 6 months, but not with baseline ADAS-cog.

… [Continue Reading]

Filed Under: Alzheimer Disease Tagged With: Demantia

Omega-3-Rich Diet May Protect Against Alzheimer’s Disease

Megan Brooks

Increased consumption of omega-3 polyunsaturated fatty acids (PUFA) correlate significantly with lower plasma levels of beta-amyloid 42 (Aβ-42) in elderly individuals without dementia, researchers found.

The association of higher omega-3 intake and lower plasma Aβ-42 they observed was independent of age, sex, ethnicity, education, and APOE genotype and has been “linked with reduced risk of incident Alzheimer’s disease (AD) and slower cognitive decline in our cohort,” they note.

The study, from Nikolaos Scarmeas, MD, MSc, associate professor of neurology, Columbia University Medical Center in New York City, and colleagues was published online May 2 in Neurology.

“We demonstrate here that there is an association between what we eat and levels of amyloid in our blood,” Dr. Scarmeas told Medscape Medical News. “The amount of omega-3 that we consume may relate to levels of amyloid in our system, an argument suggesting a possible direct relation with Alzheimer’s type of pathology,” he added.… [Continue Reading]

Filed Under: Alzheimer Disease

Alzheimer Disease Imaging PET Scanning

PET scanning is a powerful imaging technique that enables in vivo examination of brain functions. It allows for noninvasive quantification of cerebral blood flow, metabolism, and receptor binding. PET scanning helps in understanding the disease’s pathogenesis, making the correct diagnosis, and monitoring the disease’s progression and response to treatment.[35]

PET scanning involves the introduction of a radioactive tracer into the human body, usually with an intravenous injection. A tracer is essentially a biologic compound of interest that is labeled with a positron-emitting isotope, such as carbon-11 (11 C), fluorine-18 (18 F), or oxygen-15 (15 O). These isotopes are used because they have relatively short half-lives (from minutes to < 2h), allowing the tracers to reach equilibrium in the body without exposing the subjects to prolonged radiation.… [Continue Reading]

Filed Under: Alzheimer Disease

Alzheimer Disease Imaging SPECT Scanning

Single-photon emission computed tomography (SPECT) scanning uses direct photon-emitting isotopes rather than radioisotopes. SPECT isotopes have an average half-life of 6-12 hours.

SPECT instrumentation is highly variable; therefore, use of a SPECT scanner with poor resolution can result in poor clinical performance. Positron-emission tomography (PET) scanning uses tracers that measure regional glucose metabolism (rCMRGlc). SPECT imaging is most commonly used for blood-flow measurement.

Early SPECT studies of blood flow replicated findings of functional reductions in the posterior temporal and parietal cortex. The severity of temporoparietal hypofunction has been correlated with the severity of dementia in a number of studies.… [Continue Reading]

Filed Under: Alzheimer Disease

Alzheimer Disease Imaging MRI

Many studies have shown that cerebral atrophy is significantly greater in patients with Alzheimer disease (Alzheimer’s disease) than in persons without it. However, the variability of atrophy in the normal aging process makes it difficult to use MRI as a definitive diagnostic technique. (See the images below.)

Coronal, T1-weighted magnetic resonance imaging (MRI) scan in a patient with moderate Alzheimer disease. Brain image reveals hippocampal atrophy, especially on the right side. Axial, T2-weighted magnetic resonance imaging (MRI) scan of the brain reveals atrophic changes in the temporal lobes. Axial, T2-weighted magnetic resonance imaging (MRI) scan shows dilated sylvian fissure resulting from adjacent cortical atrophy, especially on the right side. Axial, T1-weighted magnetic resonance imaging (MRI) scan shows a dilated sylvian fissure caused by adjacent cortical atrophy. Axial, T1-weighted magnetic resonance imaging (MRI) scan shows bilateral cortical atrophy with accentuated cortical sulci; there is decreased involvement in the posterior aspect. Axial, T1-weighted magnetic resonance imaging (MRI) scan shows bilateral cortical atrophy with accentuated cortical sulci; there is decreased involvement in the posterior aspect.… [Continue Reading]

Filed Under: Alzheimer Disease

Alzheimer Disease Workup

Alzheimer disease (AD) is a clinical diagnosis. However, ancillary imaging studies (eg, computed tomography [CT]; magnetic resonance imaging [MRI]; and, in selected cases, single-photon emission CT [SPECT] or positron emission tomography [PET]) and laboratory tests may be used. These tests help exclude other possible causes for dementia (eg, cerebrovascular disease, cobalamin [vitamin B12] deficiency, syphilis, thyroid disease).

Diagnostic criteria established by the National Institute on Aging (NIA) and the Alzheimer’s Association are intended principally to facilitate research. However, the NIA-AA also proposed “core clinical criteria” for diagnosis of mild cognitive impairment (MCI) by health care providers without access to cerebrospinal fluid (CSF) testing or advanced imaging.[51] The NIA-AA criteria for diagnosis of dementia due to AD are clinical, with biomarkers in an assisting, nonessential role.[52]

Filed Under: Alzheimer Disease

Alzheimer Disease Differential Diagnoses

Depression is an important consideration in the differential diagnosis of Alzheimer disease (AD). The clinical manifestations of depression overlap with those of AD. In addition, an estimated 30-50% of AD patients have comorbid depression.[53]

Depression in patients with AD appears to differ from depression in cognitively intact elderly patients. Depression in AD more often features motivational disturbances (eg, fatigue, psychomotor slowing, apathy), whereas depression in geriatric patients without cognitive impairment tends to feature mood symptoms (eg, depressed mood, anxiety, suicidality, sleep and appetite disturbances).[53]

Commonly used instruments for assessing depression (eg, Hamilton Scale for Depression, Beck Depression Inventory, Geriatric Depression Scale) were designed for use in other patient populations and may be less reliable in patients with AD. Consequently, the National Institute of Mental Health has developed provisional diagnostic criteria for depression in AD.[53]… [Continue Reading]

Filed Under: Alzheimer Disease

Alzheimer Disease Clinical Presentation

Patients with Alzheimer disease (AD) most commonly present with insidiously progressive memory loss, to which other spheres of cognitive impairment are added over several years. This loss may be associated with slowly progressive behavioral changes. After memory loss occurs, patients may also experience language disorders (eg, anomia) and impairment in their visuospatial skills and executive functions.

Patients with mild AD usually have somewhat less obvious executive, language, and/or visuospatial dysfunction. In atypical presentations, dysfunction in cognitive domains other than memory may be most apparent. In later stages, many patients develop extrapyramidal dysfunction.

Substantially less common, but biopsy or autopsy-proven, presentations include right parietal lobe syndrome, progressive aphasia, spastic paraparesis, and impaired visuospatial skills, which is subsumed under the visual variant of AD.… [Continue Reading]

Filed Under: Alzheimer Disease

Alzheimer Disease Medication

The mainstay of therapy for patients with Alzheimer disease (AD) is the use of centrally acting cholinesterase inhibitors to attempt to compensate for the depletion of acetylcholine (ACh) in the cerebral cortex and hippocampus. A partial N -methyl-D-aspartate (NMDA) antagonist is approved for treatment of moderate and severe AD. Various medications are used for treatment of secondary symptoms of AD, including antidepressants, anti-anxiety agents, and antipsychotic agents.

Class Summary

Cholinesterase inhibitors (ChEIs) are used to palliate cholinergic deficiency. All 4 currently approved ChEIs (ie, tacrine, donepezil, rivastigmine, galantamine) inhibit acetylcholinesterase (AChE) at the synapse (specific cholinesterase). Tacrine was the first agent that was approved for AD, but because of its potential to cause hepatotoxicity, it is now rarely used.… [Continue Reading]

Filed Under: Alzheimer Disease

  • 1
  • 2
  • Next Page »

Popular Topics

Alzheimer Alzheimer's Disease Alzheimer disease alzheimers atrial fibrillation Bapineuzumab Brain Cancer brain disorder Brain Tumor breast cancer Cancer cell phones coffee Community Support Concussion CPAP DBS Dementia depression ECT epilepsy Epilepsy Surgery Glioblastoma Glioblastoma Multiforme headache Headache Disorders Medical Marijuana memory sleep Metastasis migraine Minimally Invasive Surgery opioid Pain Pain Management Parkinson’s Disease Preoperative MRI sleep apnea sleep disorders stroke TBI TDCS TIA TMS Traumatic Brain Injury VNS

Topic Articles

  • ACE Inhibitors
  • Alzheimer
  • Alzheimer Disease
  • Amnesia and Memory
  • Aneurysm
  • Aneurysms
  • ARB's
  • Arrythmia
  • Artificial Disc Replacement
  • Botox
  • Brain
  • Brain Cancer
  • Brain Hemorrhage
  • Brain Metastasis
  • Brain Stimulation
  • Brain Surgery
  • Brain Tumors
  • Cancer
  • Cervical Stenosis
  • Cognition
  • Community Events
  • Concussion
  • CPAP
  • Dementia
  • Depression
  • Disc Replacement
  • Dizziness
  • Drug Overdose
  • Endoscopic Spine Surgery
  • Epidural
  • Epilepsy
  • Fibromyalgia
  • Glioblastoma Multiforme
  • Gliomas
  • Guidelines
  • Hand Tremors
  • Headache
  • Low Grade Gliomas
  • Lumbar Disc
  • Malignant Astrocytoma
  • Malignant Gliomas
  • Medical Marijuana
  • Memory
  • Migraine
  • Mild Cognitive Impairment
  • Neuromodulation
  • Neurostimulation
  • News
  • Osteoporosis
  • Pain
  • Pain Management
  • PTSD
  • Robotics
  • SI-BONE
  • Sleep Apnea
  • Spinal Cord Injury
  • Spine Robotics
  • Spine Surgery
  • Stem Cells
  • Stroke
  • Tinnitus
  • Traumatic Brain Injury

Visit Our

Health Library

Clinical Expertise

  • Auto & Workman’s Compensation
  • Brain & Spine Tumors
  • Cervical Spine Surgery
  • Computer Assisted Surgery
  • Endoscopic Lumbar Fusion
  • Endoscopic Spine Surgery
  • Endoscopy Brain
  • Endoscopy Spine
  • Epilepsy Surgery
  • Gamma Knife
  • Intra-Operative MRI
  • Kyphoplasty
  • Laser Surgery
  • Low Grade Gliomas
  • Lumbar Spine Surgery
  • Minimally Invasive Surgery
  • Movement Disorders
  • Neurosurgical Oncology
  • Pain Management
  • Pituitary Tumors
  • Radio Surgery
  • Robotic Surgery
  • Robotics Endoscopic Spine Surgery
  • Skull Base Surgery
  • Spinal Cord Injury
  • Spine Surgery
  • StemWave Non-Invasive Acoustic Wave Therapy Machine
  • Stereotactic Surgery
  • Traumatic Brain Injury
  • Trigeminal Neuralgia

VIP/Concierge Program

We offer immediate patient scheduling 24/7. Our VIP/Concierge Services Program offers a full array of services for the discerning patients and families as well as out of town or international patients and families. Learn more.

Languages Spoken

Spanish, German, French, Portuguese, Italian, Chaldean, Arabic and English.

Connect With Us

  • Email
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Locations

Troy
5107 Rochester Rd., Troy, MI 48085
Hours: Mon-Fri: 9:00 am - 5:00 pm
Birmingham
2004 Hazel St., Birmingham, MI 48009
Hours: Mon-Fri: 9:00 am - 5:00 pm
Physical Therapy & Rehabilitation
5107 Rochester Rd., Troy, MI 48085
Hours: Mon - Fri: 8:00am-5:00pm

Contact Information

Phone: (248) 723-2477
Fax: (248) 681-3209 or (248) 481-3913
eFax: (248) 671-0621
  • View Our Locations
  • Michigan Brain & Spine Surgery Center
  • Physical Therapy and Rehabilitation
  • LinkedIn Page

Copyright © 2025 Michigan Brain & Spine Surgery Center. Lucia Zamorano, MD. PLC.
All Rights Reserved · Disclaimer · Privacy Policy